Shilpa Medicare Receives USFDA Approval for Liquid Bortezomib Injection (Velcade®)

Greetings from Shilpa Medicare Limited…!

Shilpa Medicare Limited continues its trailblazing efforts in pharmaceutical innovation with the recent approval of its second NDA for Bortezomib Injection (Velcade®) by the USFDA.

This breakthrough marks the first-ever “liquid” formulation of Bortezomib, approved for both subcutaneous and intravenous administration, offering significant benefits for healthcare providers. The product is designed to improve compliance and ease of administration, enhancing patient care. This approval underscores Shilpa Medicare’s dedication to advancing cutting-edge treatments across global markets.

About Shilpa Medicare Limited

Shilpa Medicare Limited, a leader in the global pharmaceutical industry for over 30 years, focuses on “Innovating for Affordable Healthcare.” Our vertically integrated operations encompass the full pharmaceutical value chain, including APIs, finished formulations, biologics, transdermal patches, and oral films.

With nine manufacturing plants, five R&D centers, and four analytical labs, we adhere to the highest quality standards, certified by global regulatory agencies such as the USFDA, EMA, WHO-GMP, and ANVISA Brazil.

Shilpa Medicare is committed to improving patient outcomes through high-quality, affordable medicines, supported by a team of over 4,000 professionals. We aim to create a healthier, sustainable future through innovative products, partnerships, and social responsibility.

Contact

For further information or partnership opportunities, please contact us at:

• Madhav S: [email protected]
• Keshav S: [email protected]
• Hanumanth R: [email protected]